<DOC>
	<DOCNO>NCT02862977</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy association one anti-inflammatory one muscle relaxant plus caffeine compare one anti-inflammatory plus caffeine treatment osteomuscular pain adult .</brief_summary>
	<brief_title>Efficacy Safety Combination Ketoprofen Cyclobenzaprine Caffeine Osteomuscular Treatment</brief_title>
	<detailed_description>- Double-blind , randomize , multicenter - Maximal experiment duration : 9 day - 02 03 visit phone contact - Evaluate efficacy association one anti-inflammatory one muscle relaxant agent caffeine compare one muscle relaxant agent plus caffeine treatment osteomuscular pain adult . - Adverse event evaluation</detailed_description>
	<mesh_term>Musculoskeletal Pain</mesh_term>
	<mesh_term>Ketoprofen</mesh_term>
	<mesh_term>Amitriptyline</mesh_term>
	<mesh_term>Caffeine</mesh_term>
	<mesh_term>Cyclobenzaprine</mesh_term>
	<criteria>Signed Consent patient ; Participants present musculoskeletal pain , moderate moderately severe , VAS ( visual analog scale ) great 40 mm period less seven ( 7 ) day . Patients clinically significant disease investigator opinion can´t participate study ; Patients laboratory find image find investigator opinion can´t participate clinical trial ; Patients history hypersensitivity formula compound ; Participation clinical trial year prior study ; Pregnancy risk pregnancy lactate patient ; Patients use drug interfere evaluation ; History rheumatic disease , fibromyalgia , osteoarticular disease , dystonia , dystrophy myopathy , acute infectious disease , gastric duodenal ulcer gastritis ; Renal hepatic impairment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>